Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study

Journal of Clinical Oncology

Volumn 12, Issue 9, 1994, Pages 1821-1826

  Anderson, H ^a   Lund, B ^b   Bach, F ^b   Thatcher, N ^b   Walling, J ^b   Hansen, H H ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTIMETABOLITE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GEMCITABINE; HEMOGLOBIN; UREA; URIC ACID;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALOPECIA; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

EID: 0028033227     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.9.1821     Document Type: Article

References (16)

1. Bakowski MT, Crouch JC: Chemotherapy for non-small cell lung cancer. A reappraisal and look to the future. Cancer Treat Rev 10:159-172, 1983
2. Cullen MH, Joshi R, Chetiyawardana AD, et al: Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Treatment good enough to compare. Br J Cancer 58:359-361, 1988
3. Currie DC, Miles DW, Drake JS, et al: Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Cancer Chemother Pharmacol 25:380-381, 1990
4. Giron CG, Ordonez A, Jalon JI, et al: Combination chemotherapy with ifosfamide, mitomycin and cisplatin in advanced non-small cell lung cancer. Cancer Treat Rep 71:851-853, 1987
5. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer. A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
6. Hardy JR, Noble T, Smith IE: Symptom relief with moderate dose chemotherapy (mitomycin C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 60:764-766, 1989
7. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
8. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumour activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422, 1990
9. Heinemann V, Hertel LW, Grindley GB, et al: Comparison of the cellular pharmacokinetics and toxicity of 2′2′difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031, 1988
10. Xu YZ, Plunkett W: Regulation of dCMP deaminase in intact CCRF-CEM cells. Proc Am Assoc Cancer Res 30:405, 1990 (abstr 2402)
11. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
12. CPMP Working Party on Efficacy of Medicinal Products: EEC note for guidance: Good clinical practice for trials on medicinal products in the European community. Pharmacol Toxicol 67:361-372, 1990
13. Mountain CF: A new international staging system for lung cancer. Chest 89:225-233, 1986 (suppl)
14. Miller AB, Hoogstraten B, Staquet M, et al: Reporting the results of cancer treatment. Cancer 47:207-214, 1981
15. Baker LRI, Rubenberg ML, Dacie JV, et al: Fibrinogen catabolism in microangiopathic haemolytic anaemia. Br J Haematol 14:617-625, 1968
16. Brain MC, Dacie JV, O'B Hourihane D: Microangiopathic haemolytic anaemia: The possible role of vascular lesions in pathogenesis. Br J Haematol 8:358-374, 1962